VIRP Virbac SA

Virbac will enter the fast-growing poultry vaccines segment in India

Virbac will enter the fast-growing poultry vaccines segment in India



Virbac announces the signing of an agreement to acquire Globion, a leading Indian poultry vaccines specialist. This transaction will bolster our position of animal health market leader in India by extending Virbac India’s existing poultry portfolio to the growing segment of avian vaccines.

Founded in 2005, as a joint venture between Suguna Group, one of the leading Indian poultry conglomerates, and Lohmann Animal Health, a German poultry vaccines specialist, Globion has developed robust know-how and expertise in the development, manufacturing and commercialization of live and inactivated vaccines targeting a large array of avian pathogens.

Globion is based in Hyderabad where its industrial and R&D facilities employ around 120 full-time employees and generate approximately €12 million of annual revenue and is independently run by a professional team.

Sébastien Huron, chief executive officer, Virbac group said “We are extremely pleased and honored to welcome the Globion team within our Virbac family. This acquisition illustrates our 2030 Virbac vision and ambition to grow through “programmatic” M&A investing in vaccines, a key strategic axis of development, reinforcing our leadership position in India, the world’s most populous country, and completing our portfolio targeting the dynamic and promising poultry market. We will fully engage with the Globion teams and provide them with additional resources to help them perform at their best. We are united with the Suguna and Globion teams by the common ambition to create long-term value for our customers and build, through innovation, a competitive portfolio of products to support the poultry industry in India and abroad.

B.Soundararajan, founder and managing director, Suguna Group said “We started Globion primarily as a source of High Quality Affordable Poultry Vaccines for Suguna Foods. In the last ten years, Globion has rapidly transformed into a fast-growing poultry biologicals company crossing 1 billion rupees of revenues by consistently gaining market share in India & export markets. By associating with a strategic partner having long term vision, infrastructure and deep understanding of animal health in Indian and global markets, we see immense potential for Globion to reach greater heights. Virbac comes out as the right choice for us since Virbac and Suguna share a common vision of adding value to the poultry industry and Virbac’s acquisition of Globion is a significant step in that direction. We will continue to remain a key customer of Globion/Virbac in the future and our best wishes to both Globion/Virbac teams for continued success.”

Veda Corporate Advisors were the advisors to Suguna and Globion in this transaction.





Always working for animal health

At Virbac, we provide innovative solutions to veterinarians, breeders and animal owners in more than 100 countries around the world. Covering more than 50 species, our range of products and services makes it possible to diagnose, prevent and treat the majority of pathologies. Every day, we are committed to improving the quality of life of animals and together shaping the future of animal health.



Press contact - Libre Mullenlowe Agency

Camille Guaine – – 39

Attachment



EN
09/10/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Virbac SA

 PRESS RELEASE

Virbac : Declaration of the number of shares and voting rights 04/2025

Virbac : Declaration of the number of shares and voting rights 04/2025 DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital(Article 223-16 of the General regulations of the French Financial Market Authority – Autoritédes Marchés Financiers) Quotation place: Euronext ParisCompartiment AISIN code: FR0000031577 DateTotal number of shares representing the share capitalTotal number of voting rightsApril, 30 20258 390 660Gross total of voting rights : 12 705 921Net total* of voting rights : 12 693 085...

 PRESS RELEASE

Virbac : Déclaration d'actions et de droits de vote 04/2025

Virbac : Déclaration d'actions et de droits de vote 04/2025 DECLARATION D’ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d’actions composant le capital(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Place cotation : Euronext ParisCompartiment ACode ISIN : FR0000031577 DATENombre total d’actions composant le capital socialNombre total de droits de vote30 Avril 20258 390 660Total brut de droits de vote : 12 705 921Total net* de droits de vote : 12 693 085 Total net* = nombre total de droits de vote attachés au no...

 PRESS RELEASE

Virbac : Rapport Annuel Virbac au 31 décembre 2024 (ESEF)

Virbac : Rapport Annuel Virbac au 31 décembre 2024 (ESEF) Veuillez trouver le Rapport Annuel du Groupe au format ESEF au 31 décembre 2024. Pièce jointe

 PRESS RELEASE

Virbac : Public release of Virbac Annual Report at 31 December 2024

Virbac : Public release of Virbac Annual Report at 31 December 2024 The Group released and filed its 2024 Annual Report with the French “Autorité des marchés financiers”, at the ESEF Format. Additionally, the report is attached at the PDF format. The document is also available on the corporate website, at corporate.virbac.com, under “Investors”, “Financial Reports” at the ESEF format and PDF format. Attachments

 PRESS RELEASE

Virbac : Communiqué de mise à disposition du Rapport Annuel au 31 déce...

Virbac : Communiqué de mise à disposition du Rapport Annuel au 31 décembre 2024 Le Groupe annonce avoir mis à la disposition du public et déposé auprès de l’Autorité des marchés financiers son Rapport Annuel au format ESEF au 31 décembre 2024. Le rapport annuel est par ailleurs disponible dans sa version PDF en pièce jointe. Enfin, le rapport annuel peut être consulté sur le site internet du Groupe, à l’adresse corporate.virbac.com, dans la rubrique « Investisseurs», puis « Rapports financiers », au format XBRL et au format PDF. Pièces jointes ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch